Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Telix Pharmaceuticals Ltd. ( (AU:TLX) ).
Telix Pharmaceuticals Ltd. has released its latest corporate governance statement in compliance with ASX Listing Rules. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council Principles and Recommendations for the financial year ending December 31, 2024. This move reinforces Telix’s commitment to transparency and accountability, potentially strengthening its position in the market and assuring stakeholders of its robust governance practices.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using targeted radiation. The company primarily serves the medical sector, with a concentration on oncology and rare diseases.
YTD Price Performance: 22.55%
Average Trading Volume: 4,376
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.81B
Learn more about TLX stock on TipRanks’ Stock Analysis page.